Tango Therapeutics and Erasca Announce Phase 1/2 Study Update for PRMT5 Inhibitor
Tango Therapeutics and Erasca have provided an update regarding their ongoing Phase 1/2 clinical study of an oral PRMT5 inhibitor.
Stocks · News reference
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68
HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $66 to $68.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Tango Therapeutics CEO to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference
Tango Therapeutics announced that its President and CEO, Malte Peters, M.D., will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026.
Tango Therapeutics Announces Promising Phase 1/2 Results for Vopimetostat and Daraxonrasib in Pancreatic Cancer
Tango Therapeutics reported positive clinical data from its Phase 1/2 study of vopimetostat in combination with daraxonrasib for patients with metastatic pancreatic ductal adenocarcinoma.
8-K filing — Tango Therapeutics, Inc. (TNGX)
Filed: 2026-10-23 AccNo: 0001193125-26-429423 Size: 12 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Outperform rating.
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
Tango Therapeutics announced it will present updated Phase 1/2 study data on vopimetostat combined with daraxonrasib or zoldonrasib for treating MTAP-deleted RAS-mutant metastatic pancreatic and lung cancers at the ESMO Congress 2026 in Madrid. The company will also host a PDAC-focused investor webcast on October 23, 2026.